HONG KONG – For the first time in 16 years, China is planning to implement an updated version of its drug administration law. The CFDA also is set to revise the country's provisions for drug registration in efforts to upgrade its health care industry. Major proposed changes to the drug administration law which covers both pharmaceuticals and medical devices –are intended to reduce regulations in line with other major markets.
HONG KONG – China has approved a domestically developed vaccine for the deadly Ebola virus and is now the third country in the world, after the U.S. and Russia, with an approved vaccine. The CFDA-approved vaccine was co-developed by the military-backed Bioengineering Institute of the Chinese Academy of Military Medical Sciences and private drugmaker Cansino Biologics Inc., of Tianjin.
HONG KONG – China has approved a domestically developed vaccine for the deadly Ebola virus and is now the third country in the world, after the U.S. and Russia, with an approved vaccine. The CFDA-approved vaccine was co-developed by the military-backed Bioengineering Institute of the Chinese Academy of Military Medical Sciences and private drugmaker Cansino Biologics Inc., of Tianjin.
HONG KONG – Research in T-cell therapy has been gaining momentum, with biotech giants like Gilead Sciences Inc. keenly investing in the area. Meanwhile, Lion TCR Pte. Ltd., a smaller company based in Singapore, is also seeing progress with its T-cell therapy treatment for hepatocellular carcinoma (HCC).
HONG KONG – Research in T-cell therapy has been gaining momentum, with biotech giants like Gilead Sciences Inc. keenly investing in the area. Meanwhile, Lion TCR Pte. Ltd., a smaller company based in Singapore, is also seeing progress with its T-cell therapy treatment for hepatocellular carcinoma (HCC).
HONG KONG – After collecting $57 million in a series B round, Hangzhou Just Biotherapeutics Ltd. venture is now looking to build on the technology platform provided by its U.S.-based parent to focus on completing a new manufacturing plant in China designed to lower the cost of biosimilars and new biologics.
HONG KONG – After collecting $57 million in a series B round, Hangzhou Just Biotherapeutics Ltd. venture is now looking to build on the technology platform provided by its U.S.-based parent to focus on completing a new manufacturing plant in China designed to lower the cost of biosimilars and new biologics.
HONG KONG – Aware of the challenges that lie ahead in China and the need for further investment to expand, drug, device and medical products distributor Cardinal Health may be looking for ways to divest some of its operations, announcing that it has “begun to explore strategic alternatives to support its next stage of growth.”
